🚀 VC round data is live in beta, check it out!
Addex Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Addex Therapeutics and similar public comparables like Bolt Biotherapeutics, Stenocare, CalciMedica, Opsy Holding and more.
Addex Therapeutics Overview
About Addex Therapeutics
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Founded
2007
HQ
Employees
2
Website
Sectors
Financials (FY)
EV
$6M
Addex Therapeutics Financials
Addex Therapeutics reported last fiscal year revenue of $508K and negative EBITDA of ($6M).
In the same fiscal year, Addex Therapeutics generated ($6M) in EBITDA losses and $9M in net income.
Revenue (LTM)
Addex Therapeutics P&L
In the most recent fiscal year, Addex Therapeutics reported revenue of $508K and EBITDA of ($6M).
Addex Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $508K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1150%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (664%) | XXX | XXX | XXX |
| Net Profit | — | XXX | $9M | XXX | XXX | XXX |
| Net Margin | — | XXX | 1746% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Addex Therapeutics Stock Performance
Addex Therapeutics has current market cap of $9M, and enterprise value of $6M.
Market Cap Evolution
Addex Therapeutics' stock price is $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6M | $9M | 0.3% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAddex Therapeutics Valuation Multiples
Addex Therapeutics trades at 12.0x EV/Revenue multiple, and (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Addex Therapeutics Financial Valuation Multiples
As of March 30, 2026, Addex Therapeutics has market cap of $9M and EV of $6M.
Equity research analysts estimate Addex Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Addex Therapeutics has a P/E ratio of 1.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.8x) | XXX | XXX | XXX |
| P/E | — | XXX | 1.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Addex Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Addex Therapeutics Margins & Growth Rates
Addex Therapeutics' revenue in the last fiscal year declined by (75%).
Addex Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $2.0M for the same period.
Addex Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (75%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1150%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (55%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 415% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 108% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 782% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Addex Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bolt Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Stenocare | XXX | XXX | XXX | XXX | XXX | XXX |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Opsy Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Iterum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Addex Therapeutics M&A Activity
Addex Therapeutics acquired XXX companies to date.
Last acquisition by Addex Therapeutics was on XXXXXXXX, XXXXX. Addex Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Addex Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAddex Therapeutics Investment Activity
Addex Therapeutics invested in XXX companies to date.
Addex Therapeutics made its latest investment on XXXXXXXX, XXXXX. Addex Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Addex Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Addex Therapeutics
| When was Addex Therapeutics founded? | Addex Therapeutics was founded in 2007. |
| Where is Addex Therapeutics headquartered? | Addex Therapeutics is headquartered in Switzerland. |
| How many employees does Addex Therapeutics have? | As of today, Addex Therapeutics has over 2 employees. |
| Who is the CEO of Addex Therapeutics? | Addex Therapeutics' CEO is Tim Dyer. |
| Is Addex Therapeutics publicly listed? | Yes, Addex Therapeutics is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Addex Therapeutics? | Addex Therapeutics trades under ADXN ticker. |
| When did Addex Therapeutics go public? | Addex Therapeutics went public in 2007. |
| Who are competitors of Addex Therapeutics? | Addex Therapeutics main competitors are Bolt Biotherapeutics, Stenocare, CalciMedica, Opsy Holding. |
| What is the current market cap of Addex Therapeutics? | Addex Therapeutics' current market cap is $9M. |
| What is the current revenue of Addex Therapeutics? | Addex Therapeutics' last fiscal year revenue is $508K. |
| What is the current EV/Revenue multiple of Addex Therapeutics? | Current revenue multiple of Addex Therapeutics is 12.0x. |
| Is Addex Therapeutics profitable? | No, Addex Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.